Background. A 6-month pilot intervention trial was conducted to determine whether adoption of a plant-based diet, reinforced by stress reduction, could reduce the rate of prostate-specific antigen (PSA) increase, a marker of disease progression, in asymptomatic, hormonally untreated patients experiencing consistently increasing PSA levels after surgery or radiation. Methods. A pre—post design was used to examine (1) the effect of intervention on potential mediators of disease progression, including body composition and weight-related biomarkers (sex steroid hormones and cytokines), and (2) whether changes in these variables were associated with change in rate of PSA increase. The baseline rate of PSA increase (from the time of posttreatment recurrence to the start of intervention) was ascertained from medical records. Body composition and biomarkers were assessed at baseline (prior to intervention), during the intervention (3 months), and at the end of the intervention (6 months). Changes in body composition and biomarkers were determined and compared with rates of PSA increase over the corresponding time intervals. Results. There was a significant reduction in waist-to-hip ratio (P = .03) and increase in circulating sex hormone binding globulin (P = .04). The rate of PSA increase decreased from the preintervention period (PSA slope = 0.059) to the period from 0 to 3 months (PSA slope = 0.002, P < .01) and increased slightly, although not significantly, from 0 to 3 months to the period from 3 to 6 months (0.029, P = .43). Conclusions. Adoption of a plant-based diet and stress reduction may reduce central adiposity and improve the hormonal milieu in patients with recurrent PC. Changes in the rate of increase in PSA were in the same direction as changes in waist-to-hip ratio and opposite those of sex hormone binding globulin, raising the possibility that the effect of the intervention may have been mediated, in part, by these variables.
Pienta KJEtiology, epidemiology, and prevention of carcinoma of the prostate . In: Walsh PC, ed. Campbell's Urology. 7th ed. Philadelphia, Pa: Saunders; 1998 :2489-2496.
2.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PCNatural history of progression after PSA elevation following radical prostatectomy . JAMA. 1999;281:1591-1597.
3.
Patel A., Dorey F., Franklin J., deKernion JBRecurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997;158:1441-1445.
4.
Zagars GK, Pollack A.Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol . 1997;44:213-221
5.
D'Amico AV, Moul JW, Carroll PR, Sun L., Lubeck D., Chen M-H.Surrogate end-point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-1383
6.
Vollmer RT, Dawson NA, Vogelzang NJThe dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of Cancer and Leukemia Group B study 9181 of megestrol acetate . Cancer. 1998;83:1989-1994
7.
Messing EM, Manola J., Sarosoy M., Wilding G., Crawford ED, Trump D.Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New Engl J Med. 1999;341:1781-1788.
8.
Mayer FJ, Crawford EDThe role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy. Urol Clin North Am. 1994;21:707-715.
9.
Heber D., Fair WR, Ornish D.Nutrition and Prostate Cancer: A Monograph from the CaPCure Nutrition Project . 2nd ed. Santa Monica, CA: CaPCure. 1998.
10.
Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, eds. Cancer Incidence in Five Continents. Lyon, France: IARC Scientific Publications143; 1999.
11.
Shimuzu H., Ross RK, Bernstein L., Yatani R., Henderson BE, Mack TMCancers of the prostate and breast among Japanese and white immigrants to Los Angeles County. Br J Cancer. 1991;63:963-966.
12.
Muir CS, Nectoux J., Staszewski J.The epidemiology of prostatic cancer: geographical distributions and time-trends . Acta Oncol. 1991;30:133-140.
13.
Fair WR, Fleshner NE, Heston WDCancer of the prostate: a nutritional disease? Urology . 1997;50:840-848.
14.
Kolonel LNFat, meat, and prostate cancer. Epidemiol Rev. 2001;23:72-81.
15.
Chan JM, Giovannucci ELDairy products, calcium, and vitamin D and risk of prostate cancer . Epidemiol Rev. 2001;23:87-92.
16.
Ghosh J., Myers CEArachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Comm. 1997;233:418-423.
17.
Chan J., Giovannucci ELVegetables, fruits, associated micronutrients, and risk of prostate cancer . Epidemiol Rev. 2001;23: 82-86.
18.
Cohen JH, Kristal AR, Stanford JLFruit and vegetable intake and prostate cancer risk. J Natl Cancer Inst. 2000;92: 61-68.
19.
Brooks JD, Paton VG, Vidanes G.Potent induction of phase 2 enzymes in human prostate cancer cells by sulforaphane . Cancer Epidemiol Biomarkers Prev. 2001;10:949-954.
20.
Carter JP, Saxe GA, Newbold V., Peres CE, Campeau RJ, Bernal-Green L.Hypothesis: dietary management may improve survival from nutritionally linked cancers based on analysis of representative cases. J Am Coll Nutr. 1993;12:209-226.
21.
Saxe GA, Hebert JR, Carmody JF, et al. Can diet in conjunction with stress reduction affect the rate of increase in prostate specific antigen after biochemical recurrence of prostate cancer? J Urol. 2001;166:2202-2207.
22.
Ornish D., Weidner G., Fair W., et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol. 2005;174:1065-1070.
23.
Amling CLRelationship between obesity and prostate cancer. Curr Opin Urol. 2005;15:167-171.
24.
Buschemeyer WC III, Freedland SJObesity and prostate cancer: epidemiology and clinical implications. Eur Urol. 2007;52:331-343.
25.
Amling CL, Riffenburgh RH, Sun L., et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22:439-445.
26.
Palma D., Pickles T., Tyldesley S.Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer. BJU Int. 2007 ;100:315-319.
27.
Freedland SJ , Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004;22:446-453.
28.
Strom SS, Kamat AM, Gruschkus SK, et al. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer. 2006; 107:631-639.
29.
Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TCElevated levels of circulating interleukin-6 and transforming growth factor-beta 1 in patients with metastatic prostatic carcinoma. J Urol . 1999;161:182-187.
30.
Michalaki V. , Syrigos K., Charles P., Waxman J.Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 2004;90:2312-2316.
31.
Denmeade SR , Isaacs JTDevelopment of prostate cancer treatment: the good news. Prostate. 2004;58:211-24.
32.
Lytton B.Prostate cancer: A brief history and the discovery of hormonal ablation treatment . J Urol. 2001;165(6, pt 1):1859-1862.
33.
Horoszewicz JS, Murphy GPProspective new developments in laboratory research and clinical trials in prostatic cancer. Cancer. 1990;66(5 suppl):1083-1085.
34.
Peehl DMPrimary cell cultures as models of prostate cancer development. Endocr Relat Cancer. 2005;12:19-47.
35.
Freedland SJObesity and prostate cancer: a growing problem . Clin Cancer Res. 2005;11(19, pt 1):6763-6766.
36.
Barnard RJProstate cancer prevention by nutritional means to alleviate metabolic syndrome . Am J Clin Nutr.2007;86(suppl): 889S-893S. .
37.
Tchernof A. , Després JPSex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm Metab Res. 2000;32:526-536.
38.
Platz EA, Leitzmann MF, Rifai N., et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era . Cancer Epidemiol Biomarkers Prev. 2005;14:1262-1269.
39.
Severi G., Morris HA, MacInnis RJ, et al. Circulating steroid hormones and the risk of prostate cancer . Cancer Epidemiol Biomarkers Prev. 2006;15: 86-91.
40.
Saxe GA, Major JM, Nguyen JY, Freeman KM, Downs TM, Salem CEPotential attenuation of disease progression in recurrent prostate cancer with plant-based diet and stress reduction. Integr Cancer Ther. 2006;5:206-213.
41.
Abate N., Haffner SN, Garg A., Peshock RM, Grundy SMSex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab. 2002;87:4522-4527.
42.
Barnard RJ, Aronson WJ, Tymchuk CN, Ngo THProstate cancer: another aspect of the insulin resistance syndrome?Obesity Rev. 2002;3:303-308. 2002 .
43.
Hsing AW, Sakoda LC, Chua S. Jr.Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86: s843-s857.
44.
Gann PH, Hennekens CH, Ma J., Longcope C., Stampfer MJProspective study of sex hormone levels and risk of prostate cancer . J Natl Cancer Inst. 1996;88:1118-1126.
45.
Key TJ, Allen NE, Verkasalo PK, Banks E.Energy balance and cancer: the role of sex hormones. Proc Nutr Soc. 2001;60: 81-89.
46.
Dunn JF, Nisula BC, Rodbard D.Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981 ;53:58-68. .
47.
Greenberg AS , Obin MSObesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr.2006; 83:461S-465S.
48.
Dandona P., Aljada A., Chaudhuri A., Mohanty P., Garg R.Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448-1454. .
49.
Nelson WG, De Marzo AM, DeWeese TL, Isaacs WBThe role of inflammation in the pathogenesis of prostate cancer. J Urol. 2004;172(5, pt 2):S6-S11. .
50.
Platz EA, De Marzo AMEpidemiology of inflammation and prostate cancer. J Urol. 2004;171:S36-S40.
Maes M., Song C., Lin A., et al. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety . Cytokine. 1998;10:313-318.
53.
Nguyen JY, Major JM, Knott CJ, Freeman KM, Downs TM, Saxe GAAdoption of a plant-based diet by patients with recurrent prostate cancer . Integr Cancer Ther. 2006;5: 214-223.
54.
World Cancer Research Fund/American Institute for Cancer Research.Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: American Institute for Cancer Research; 2007.
